Modulation of anxiety through blockade of anandamide hydrolysis

Details Modulation of anxiety through blockade of anandamide hydrolysis Modulation of anxiety through blockade of anandamide hydrolysis

C - Chemistry, Metallurgy

07

C

C07C 271/00 (2006.01) A61K 31/21 (2006.01) C07C 271/56 (2006.01) C07C 275/54 (2006.01) C07C 311/29 (2006.01)

Patent

CA 2501506

Fatty acid amide hydrolase inhibitors of the Formula (I) are provided, wherein X is NH, CH2, O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl; substituted or unsubstituted terphenylyl; substituted or unsubstituted cycloalkyl, heteroaryl, or alkyl; and R1 and R2 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted phenyl, substituted or unsubstituted biphenylyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; with the proviso that if Z is O, one of R1 and R2 is absent, and that, if Z is N, optionally R1 and R2 may optionally be taken together to form a substituted or unsubstituted N- heterocycle or substituted or unsubstituted heteroaryl with the N atom to which they are each attached. Pharmaceutical compositions comprising the compounds of Formula (I) and methods of using them to inhibit FAAH and/or treat appetite disorders, glaucoma, pain, insomnia, and neurological and psychological disorders including anxiety disorders, epilepsy, and depression are provided.

L'invention concerne des inhibiteurs d'hydrolase d'amide d'acide gras de formule (I). Dans cette formule, X est NH, CH¿2?, O, ou S; Q est O ou S; Z est O ou N; R est une fraction aromatique du groupe comprenant aryle substitué ou non; biphénylyle substitué ou non, naphtyle substitué ou non, et phényle substitué ou non; terphénylyle substitué ou non; cycloalkyle, hétéroaryle, ou alkyle substitué ou non; et R¿1? et R¿2? sont choisis indépendamment dans le groupe comprenant H, alkyle substitué ou non, hétéroalkyle substitué ou non, et phényle substitué ou non, biphénylyle substitué ou non, aryle substitué ou non, et hétéroaryle substitué ou non; à condition que Z soit O, que R¿1? ou R¿2? soit absent, et que, si Z est N, éventuellement R¿1? et R¿2? puissent être réunis pour former un hétérocycle-<I>N</I> substitué ou non ou un hétéroaryle substitué ou non avec l'atome N auquel ils sont fixés. L'invention concerne également des compositions pharmaceutiques renfermant les composés décrits et des procédés relatifs à leur utilisation pour l'inhibition de FAAH et/ou le traitement des affections suivantes: troubles de l'appétit, glaucome, douleur, insomnie, et troubles neurologiques et psychologiques dont les troubles liés à l'anxiété, l'épilepsie et la dépression.

Affiliated with

Also associated with

Rating

Modulation of anxiety through blockade of anandamide hydrolysis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modulation of anxiety through blockade of anandamide hydrolysis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of anxiety through blockade of anandamide hydrolysis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1718227